BFM
TARS icon

Boothbay Fund Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Boothbay Fund Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,000
Closed -$872K – 1845
2024
Q1 		$872K Hold
24,000
– – 0.02% 798
2023
Q4 		$486K Buy
+24,000
New +$401K 0.01% 997

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's TARS Position: Q1 2026 in Review

Boothbay Fund Management held its Tarsus Pharmaceuticals (TARS) position steady in Q1 2026 at 4,324 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Boothbay Fund Management first reported a position in TARS in Q3 2023 and has held it in 11 quarters since. The position peaked at $9.06M in Q3 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Boothbay Fund Management held 4,324 shares of Tarsus Pharmaceuticals worth $303K as of Q1 2026.
  • Boothbay Fund Management left its Tarsus Pharmaceuticals share count unchanged in Q1 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1605 holding.
  • Boothbay Fund Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Boothbay Fund Management's Tarsus Pharmaceuticals position peaked at $9.06M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.